Med Lett Drugs Ther. 2015 Oct 12;57(1479):139-40.
A significant decrease in cardiovascular mortality has been reported with use of the SGLT2 inhibitor empagliflozin (Jardiance) to treat patients with type 2 diabetes who have established cardiovascular disease. The mechanism of this reduction is unclear, and these results may not apply to patients with type 2 diabetes and less advanced cardiovascular disease. Whether the increase in fractures reported with canagliflozin (Invokana) could also occur with empagliflozin remains to be established. All SGLT2 inhibitors are only modestly effective for treatment of diabetes.
据报道，使用钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂恩格列净（欧唐静）治疗已确诊心血管疾病的2型糖尿病患者，可显著降低心血管疾病死亡率。这种降低的机制尚不清楚，这些结果可能不适用于患有2型糖尿病且心血管疾病不太严重的患者。恩格列净是否也会出现与卡格列净（怡可安）相关的骨折增加情况仍有待确定。所有SGLT2抑制剂治疗糖尿病的效果都只是中等程度有效。
